TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).-MedSci.cn

TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Rini, BI; Pal, SK; Escudier, B; Atkins, MB; Hutson, TE; Porta, C; Verzoni, E; Needle, MN; McDermott, DF

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (7):

科室
- - 订阅+
  - 更多科室
工具
服务